药明合联2024年业绩亮眼,净利润同比增长277.2%

每日经济新闻
25 Mar

药明合联公布2024年度业绩,营业收入同比增长90.8%,至40.52亿元;净利润同比增长277.2%,至12.4亿元。此前同属药明系的药明康德发布2024年业绩后大涨,其2024年营收同比增长5.2%(剔除去年新冠商业化项目),经调整Non-IFRS归母净利润105.8亿元,净利润率创历史新高。恒生医药ETF(159892)持仓药明康德、药明生物、药明合联等知名标的;近期处于年报密集披露期,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10